This blog is all about current FDA approved drugs to treat the hepatitis C virus (HCV) with a focus on treating HCV according to genotype, using information extracted from peer-reviewed journals, liver meetings/conferences, and interactive learning activities.
Risk Of Developing Liver Cancer After HCV Treatment
- Home
- Newly Diagnosed With Hep C? Or Considering Treatment?
- All FDA Approved Drugs To Treat Hepatitis C
- Hepatitis C Genotypes and Treatment
- Mavyret (glecaprevir/pibrentasvir)
- Vosevi (Sofosbuvir/Velpatasvir/Voxilaprevir)
- Epclusa® (Sofosbuvir/Velpatasvir)
- Harvoni® (Ledipasvir/Sofosbuvir)
- VIEKIRA XR/VIEKIRA Pak
- Zepatier(Elbasvir/Grazoprevir)
- Cure - Achieving sustained virologic response (SVR) in hepatitis C
- HCV Liver Fibrosis
- FibroScan® Understanding The Results
- HCV Cirrhosis
- Staging Cirrhosis
- HCV Liver Cancer
- Risk Of Developing Liver Cancer After HCV Treatment
- Treating Elderly HCV Patients
- Fatty Liver Disease: NAFLD/NASH
- Current research articles on ailments that may be related to HCV
- Is There A Natural Way To Improve Liver Fibrosis?
- Can Food Or Herbs Interact With Conventional Medical Treatments?
Friday, August 5, 2011
Thrombosis-The 50-year quest to replace warfarin
The 50-year quest to replace warfarin
For over 50 years, thrombosis has been treated with the anticoagulant warfarin. This video describes the timeline from the discovery of warfarin through to the recent approval of new oral anticoagulants that could provide long-sought alternatives to warfarin.
Read More From Nature Here
Related;
Liver Health: Deep vein thrombosis (DVT) In Cirrhosis
Hospitalized cirrhotics are at increased risk for venous thromboembolism (VTE) up until age 45 but not afterward, a new study suggests. Patients hospitalized with cirrhosis patients "should be considered for VTE prophylaxis," especially those younger than 45 years, Dr. Harry Wu and Dr. Geoffrey C. Nguyen conclude in an article in Clinical Gastroenterology and Hepatology, published online May 26th. Liver disease can both increase and decrease the risk of VTE due to its effects on the coagulation cascade, the clinicians from Mount Sinai Hospital and the University of Toronto in Ontario, Canada, note in their report...Read More...
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment